An early-stage venture capital firm with offices in USA and China has 2 business practices; managing a seed fund that invests exclusively in healthcare and life sciences, and an advisory business primarily for western biotech or life science companies that are looking to establish business opportunities and partnerships in greater China. The firm is starting to expand their network into the Middle East, especially Turkey. The firm is looking for Seed opportunities but is open to participation in Pre-Seed and Series A on a case by case basis. The typical check size is $50-250K in the form of equity or convertible notes. The firm will consider opportunities anywhere in the world.

The firm will look at all subsectors and indications but is not investing in immunotherapy or cancer at this time. The firm is particularly interested in chronic disease, especially diabetes and is starting to look at neurodegenerative diseases as well.  The firm is not doing biotech deals, but they’ve done deals in Healthcare IT and the AI space. The firm is focusing on diagnostics and digital health at the moment.

The firm is open to all management teams but prefers teams with prior start-up experience. The firm is not looking to do small participations in big rounds and would prefer to do investments where their stake has a meaningful impact on the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a family office invests in all sectors of the life sciences, looking for companies that are 2-5 years from exit. The firm invests globally, although they have a preference for companies based in the UK and in Central/Eastern Europe. The firm invests from Seed-Series C, and generally will invest $1-5M per round.

The firm is both sector and indication agnostic, and is less focused on stage of development and more focused on time to exit, looking for companies with a strategy that will allow them to exit within 2-5 years after the investment.

The firm generally does not act as a lead investor. The firm does not generally take a board seat, and is usually a silent investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech early stage investment firm headquartered in Asia invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In the country they are headquartered in, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A public biopharmaceutical company with over 20 years operation in China’s pharmaceutical industry is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm is interested in in-licensing clinical stage assets for development, while collaborative R&D can also be considered. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe. The firm is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilars, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, while it can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment platform with around €4B in assets under management spans both venture and private equity. Since its inception, the firm has completed 200+ investments. The firm’s latest fund, a dedicated healthcare and life science fund, targets venture and growth stage Tech-Enabled Medicine companies operating at the convergence of health, life sciences and technology. Investment sizes can range from $5M (Seed to Series A) to $50M (Crossover), with average initial check sizes expected to be around $10-15M, and a significant portion will be reserved for later rounds. The firm’s sweet spot is in Series B to C companies.

The firm invests globally across Asia, North America, and Europe (including Middle East). The firm is particularly interested in companies that want to expand to other geographic markets and assist companies to scale globally.

The firm will invest in six areas at the convergence of health, life sciences and technology:

1. Life science tools – tools enabling advanced diagnostics / treatment: automated cell manufacturing & supply chain management for cell therapy, single cell manipulation, multi-omics consumables & reagents
2. Diagnostics – enable more precise diagnostics, early detection, treatment support: clinical multi-omics, companion Dx, digital imaging / pathology with AI, clinical decision support systems
3. Clinical trial enablement – finding the right patient and supporting distributed trials: patient subpopulation selection, trial site matching, virtual / decentralized trials, continuous trial monitoring, real world evidence
4. Advanced Therapeutics – new modalities enabled by new technology: AI-driven drug discovery, cell & gene therapy, gene editing, microbiome, protein modulation, etc.
5. New care models – changing point of care & virtual treatments: telehealth, digital therapeutics, digital mental health, wearables, chronic disease monitoring solutions
6. Next-gen devices / materials – implantables enabled by novel materials / miniaturization, connected devices: biopolymers, non-invasive treatments, monitoring, closed loop therapies, robotic surgery, 3D printing

The firm likes to see strong management teams with proven track record and problem-solving skills or outstanding scientific founders.

The company should have innovation with impact, a clear development and regulatory approval pathway, and capital efficiency (defined timeline and budget and prudent approach to valuation). The firm can lead and co-invest depending on the investment opportunity, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.